TNFRSF4 and breast carcinoma: Furthermore, to assess the broader applicability of our findings, we confirmed the synergistic anti-tumor effects of MWA and OX40 agonism in additional preclinical models of B16-F10 melanoma and 4T1 breast cancer (Supplementary Figure 1), suggesting the potential for broader translational relevance.